Abstract Number: 2534 • 2019 ACR/ARP Annual Meeting
Vitamin D Reduces Cardiovascular Risk Factors in SLE
Background/Purpose: Vitamin D has effects on the cardiovascular system, including decreased renin-angiotensin, decreased insulin resistance, increased vascular relaxation and decreased vascular smooth muscle cell proliferation,…Abstract Number: 2535 • 2019 ACR/ARP Annual Meeting
Identifying Subgroups of SLE Patients with Differential Responses to a BLyS Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data
Background/Purpose: Given the heterogeneity of systemic lupus erythematosus (SLE), the effect of any intervention is expected to vary. The ability to identify those most and…Abstract Number: 2536 • 2019 ACR/ARP Annual Meeting
Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States
Background/Purpose: Therapeutic drug monitoring of whole blood Hydroxychloroquine (HCQ) can help identify patients at risk of flares due to underexposure (e.g. severe non-adherence, < 200…Abstract Number: 2537 • 2019 ACR/ARP Annual Meeting
Influential Factors in Promoting Treat-to-Target for Systemic Lupus Erythematosus via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)
Background/Purpose: Treating to target is routine in rheumatoid arthritis, but no comparable standard has been defined for SLE. In 2015, the definition of Lupus Low Disease Activity State (LLDAS) was…Abstract Number: 2538 • 2019 ACR/ARP Annual Meeting
Importance of Serum Phosphatidylserine-Specific Phospholipase A1 (PS-PLA1) as a Novel Disease Activity Biomarker of Systemic Lupus Erythematous
Background/Purpose: Phosphatidylserine-specific phospholipase A1 (PS-PLA1) is a secreted lipase that is proposed to be a producing enzyme for lysophosphatidylserine (LysoPS), which is an emerging lipid…Abstract Number: 2539 • 2019 ACR/ARP Annual Meeting
Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Hydroxychloroquine (HCQ) is recommended in all patients with systemic lupus erythematosus (SLE). Studies suggest that a significant proportion of subjects are non-adherent to daily…Abstract Number: 2540 • 2019 ACR/ARP Annual Meeting
Impact of IL34, IFN-α and IFN-λ1 on Disease Activity of SLE Patients in Egypt
Background/Purpose: SLE is a systemic inflammatory and autoimmune disease. IL-34 plays pivotal roles in the proliferation and differentiation of mononuclear phagocyte cells, osteoclastogenesis and inflammation.…Abstract Number: 2541 • 2019 ACR/ARP Annual Meeting
Pharmacokinetics of Hydroxychloroquine in Systemic Lupus Erythematosus Patients with Renal Impairment
Background/Purpose: A low glomerular filtration rate (GFR: < 60 mL/min/1.73 m2) is an established risk of hydroxychloroquine (HCQ) retinopathy and is presumably related to higher…Abstract Number: 2542 • 2019 ACR/ARP Annual Meeting
An Updated Meta-Analysis of the Efficacy and Safety of Mycophenolate Mofetil in the Induction Treatment of Chinese Patients with Lupus Nephritis
Background/Purpose: Achieving clinical remission while reducing toxicity are primary objectives in the treatment of lupus nephritis (LN). Mycophenolate mofetil (MMF) has demonstrated efficacy benefits with…Abstract Number: 2543 • 2019 ACR/ARP Annual Meeting
Meta-Analysis Examining the Clinical Significance of Monitoring of Hydroxychloroquine Levels in SLE
Background/Purpose: Despite the pivotal role hydroxychloroquine (HCQ) plays in treating SLE, less than 50% of patients take HCQ as prescribed. Nonadherence versus lack of effect…Abstract Number: 2544 • 2019 ACR/ARP Annual Meeting
Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE
Background/Purpose: Belimumab is approved as add-on therapy in active, autoantibody-positive SLE. Safety and efficacy up to 13 years has been reported in adults, but potential…Abstract Number: 2545 • 2019 ACR/ARP Annual Meeting
Belatacept in Systemic Lupus Erythematosus (SLE) Kidney Transplant Patients
Background/Purpose: Lupus nephritis (LN) ultimately requires renal replacement therapy (RRT) in 10-30% of LN patients. Thirty percent of these patients receive a kidney transplant. Belatacept…Abstract Number: 2546 • 2019 ACR/ARP Annual Meeting
Clinician’s Simple Opinion of SLE Disease Progress: Used in a Clinical Trial
Background/Purpose: Measuring improvement or worsening is problematic in lupus trials. The British Isles Lupus Assessment Group (BILAG) index often fails to capture sustained decrease in…Abstract Number: 2547 • 2019 ACR/ARP Annual Meeting
Safety Results of 50% Enrollment from a Multicenter, Randomized, Double‑blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Repository Corticotropin Injection in Patients with Systemic Lupus Erythematosus Despite Moderate‑dose Corticosteroid Use
Background/Purpose: Repository corticotropin injection (RCI) is a naturally sourced complex mixture of adrenocorticotropic hormone (ACTH1-39) analogues and other pituitary peptides that stimulates endogenous corticosteroid (CS)…Abstract Number: 2548 • 2019 ACR/ARP Annual Meeting
Abatacept Failed to Demonstrate Efficacy in an SLE Trial with Low Placebo Response Rates, Although Global Assessments Indicated Less Flare Severity
Background/Purpose: Abatacept (ABA) is a fusion protein of the extracellular domain of CTLA4 and human IgG1-Fc, constructed to inhibit B/T cell co-stimulation. Previous studies of…
ACR Meeting Abstracts